FDA and NIH Workforce Authorities Modernization Act
1/11/2023, 1:31 PMCongressional Summary of S 2700
FDA and NIH Workforce Authorities Modernization Act
(Sec. 2) This bill amends the Public Health Service Act to revise the Silvio O. Conte Senior Biomedical Research Service to: (1) increase the limit on the number of members, (2) expand eligibility for appointment, (3) set a maximum pay rate, and (4) remove the option for members to contribute to the retirement system of an institution of higher education. The Government Accountability Office (GAO) must report on these amendments.
(Sec. 3) This bill amends the Federal Food, Drug, and Cosmetic Act to grant the Food and Drug Administration (FDA) additional hiring authority for scientific, technical, or professional positions that support the development, review, and regulation of medical products. The FDA must report on its need for qualified individuals for such positions and must include a recruitment and retention plan. The GAO must report on the FDA’s ability to hire, train, and retain qualified staff.
(Sec. 4) The FDA must establish one or more Intercenter Institutes. Each institute must coordinate activities applicable to a major disease area among the FDA centers that review products. Activities may include coordinating staff with relevant expertise, streamlining product review, and enhancing interactions with patients, sponsors, and the biomedical community.
(Sec. 5) Scientific meetings directly related to the duties of a Department of Health and Human Services (HHS) professional must not be considered conferences for purposes of certain reporting requirements and restrictions on conference travel. Each division of HHS must report on scientific meeting attendance and related travel spending.
(Sec. 6) The bill revises Board of Directors membership, Executive Director compensation, and accounting for the Reagan-Udall Foundation for the FDA.
(Sec. 7) The Paperwork Reduction Act does not apply to National Institutes of Health research.
(Sec. 9) For certain indications, the FDA may rely upon a summary of clinical data to approve a supplemental application for a drug.
(Sec. 10) The bill revises provisions regarding: (1) FDA screening of the Adverse Event Reporting System, and (2) evaluation of elements to assure safe use of drugs.
The FDA must publish: (1) best practices for using the Adverse Event Reporting System, (2) criteria for publishing adverse event information, and (3) best practices for drug safety surveillance activities for newly approved medications. The FDA no longer must prepare a summary analysis of adverse drug reaction reports for recently approved drugs.
(Sec. 11) Biological products are not subject to provisions that refer to an official compendium of drug information.
(Sec. 12) The manufacturer or distributor of an investigational drug for a serious condition must publish a policy for compassionate use of the drug.
(Sec. 13) HHS must finalize the guidance entitled “Expanded Access to Investigational Drugs for Treatment Use--Qs & As.” The guidance must explain how HHS uses adverse drug event data from compassionate use.
(Sec. 14) This bill amends the Orphan Drug Act to authorize HHS to defray all the costs of development of orphan drugs (drugs for rare conditions), instead of only certain testing expenses.
(Sec. 15) HHS must facilitate the development of standards to support development and review of regenerative medicine and advanced therapies.
(Sec. 16) FDA guidance must include specified information, including the statutory provisions or regulations that are the basis for policy decisions.
(Sec. 17) The Paperwork Reduction Act does not apply to voluntary collection of information during a public health emergency or while determining whether there is a public health emergency.
(Sec. 18) The bill revises provisions regarding:
- movement of impounded drugs,
- pediatric study plans,
- reporting on drug shortages,
- reporting on inspections of establishments manufacturing drugs or medical devices,
- requests to classify medical devices,
- priority review of qualified infectious disease products,
- use of clinical investigation data from outside the United States, and
- medical gasses.
